AACC uses Cookies to ensure the best website experience. Continuing without changing Cookie settings assumes you consent to our use of cookies on this device. You can change these settings at any time, but that may impair functionality on our websites. Review our cookie and privacy policy

The Biomarker Multiplexing Capabilities Of LC-MS Technology: The Key to Unlock Personalised Preeclampsia Risk Prediction Early in Pregnancy

  • Credit:1.0 ACCENT Credit
  • Duration: 1 hr
  • Date:JAN.27.2021 1:00 PM - 02:00 PM
  • Level: Intermediate

Price: $0.00

Member Price: $0.00

This prerecorded webinar will be released on Wednesday, January 27, 2021 at 1pm EST. Convert to your time zone

Register for this webinar to learn how to implement biomarker-enabled preeclampsia risk stratification tools. With your registration, you will have access to the recording on demand through January 31, 2022.

DESCRIPTION

Managing preeclampsia risk is a cornerstone of prenatal care worldwide. Yet, until recently, the tools to assess a woman’s preeclampsia risk early in pregnancy consisted merely of scoring her against a set of risk factors. Meanwhile, clinicians monitor women for the onset of preeclampsia principally based on regular blood pressure and proteinuria (dipstick) measurements. Medical professionals for decades have been highlighting the need for biomarkers which can complement, or even replace, these existing approaches. This intense interest has identified a plethora of putative biomarkers, yet so far few have found a place in clinical care.

Join Robin Tuytten, PhD, as he discusses the current state-of-the art clinical applications in preeclampsia risk prediction. He will also discuss the intrinsic challenges of developing (biomarker based) risk predictors for syndromic conditions like pre-eclampsia and how these challenges impact biomarker development efforts.

Registrants will have access to this recording on demand through the January 31, 2022.

TARGET AUDIENCE

This activity is designed for physicians, lab supervisors, lab directors (and/or assistant directors), lab managers (supervisory and/or non-supervisory), medical technologists, point-of-care coordinators, fellows, residents, and other laboratory professionals overseeing and/or carrying out biomarker testing.

LEARNING OBJECTIVES

At the end of this activity, participants will be able to:

  • Know the right questions to ask in order to establish a purposeful translational research pipeline
  • Become familiar with a translational research pipeline for metabolite biomarker development
  • Understand the different types of preeclampsia biomarker development projects  

FACULTY

Robin TuyttenRobin Tuytten, PhD
CSO
Metabolomic Diagnostics
Cork, Ireland

ACCREDITATION STATEMENT

This education activity will be submitted to AACC for approval of up to 1 ACCENT credit(s).

SUCCESSFUL COMPLETION STATEMENT

Verification of Participation certificates are provided to registered participants based on completion of the activity, in its entirety, and the activity evaluation. For questions regarding continuing education, please email education@aacc.org.

Supported by

Agilent Logo